Posdinemab (development code BMS-986446) is an anti-tau monoclonal antibody developed by Bristol Myers Squibb (BMS) in partnership with BioArctic AB for the treatment of Alzheimer's disease and other tauopathies[@bms][@bioarctic2024]. The antibody targets phosphorylated tau protein in the mid-domain region, representing a distinct approach from both N-terminal targeting antibodies and conformational epitope-specific antibodies.
The development of posdinemab reflects BMS's commitment to the tau immunotherapy space following the discontinuation of their earlier anti-tau program. The partnership with BioArctic brings proprietary antibody technology to the collaboration, leveraging years of research on tau pathology and antibody engineering.
Tau pathology represents a critical therapeutic target in Alzheimer's disease, with neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau being closely correlated with cognitive decline[@yoshiyama2013][@wu2020]:
Pathological Cascade:
- Hyperphosphorylation of tau at multiple sites
- Formation of soluble oligomeric species
- Assembly into paired helical filaments (PHFs)
- Aggregation into neurofibrillary tangles
- Neuronal death and synaptic loss
Tau Spread Hypothesis:
- Pathological tau propagates between neurons
- Trans-synaptic spread drives disease progression
- Interception may prevent further neurodegeneration
Posdinemab specifically targets tau species that are phosphorylated at key pathological sites[@schofield2022]:
Rationale for Phospho-Targeting:
- Phosphorylated tau is more specific for AD pathology
- p-tau species are more aggregation-prone
- Phosphorylation creates novel epitopes for antibody binding
- p-tau levels correlate with disease severity
Mid-Domain Targeting:
- Mid-domain region (aa 150-250) contains multiple pathologically relevant sites
- Accessible to antibody binding in both extracellular and intracellular compartments
- Different from N-terminal (easier access) and C-terminal (microtubule binding) regions
¶ Antibody Properties
Posdinemab is engineered to selectively bind phosphorylated tau in the mid-domain region[@bms][@bioarctic2024]:
Epitope Specificity:
- Targets phosphorylated epitopes in the tau mid-domain
- Prefers aggregated over monomeric tau
- Minimal binding to non-phosphorylated tau
Binding Characteristics:
- High affinity for pathological tau species
- Humanized IgG backbone for optimal effector function
- Designed for brain penetration
Posdinemab achieves therapeutic benefit through multiple mechanisms[@sofruiti2019][@kolb2017]:
1. Direct Binding and Neutralization:
- Binds extracellular tau aggregates
- Prevents tau-tau interactions and propagation
- Neutralizes toxic oligomeric species
2. Fc-Mediated Clearance:
- Facilitates microglia-mediated clearance
- Enhances phagocytosis of pathological tau
- Activates complement cascade where appropriate
3. Prevention of Spread:
- Intercepts propagating tau species in extracellular space
- May block trans-synaptic transmission
- Could slow disease progression by limiting spread
Like all therapeutic antibodies, posdinemab faces the challenge of adequate brain exposure[@butchart2019]:
BBB Challenges:
- Limited transport across the blood-brain barrier
- Typical brain:plasma ratios of 0.1-1%
- Requires high dosing for therapeutic effect
Dosing Considerations:
- Intravenous administration
- Monthly or longer dosing intervals
- Dose selection based on preclinical and early clinical data
First-in-human Phase I studies evaluated posdinemab in healthy volunteers and patients with early Alzheimer's disease[@bms]:
Study Design:
- Randomized, double-blind, placebo-controlled
- Single ascending dose (SAD) and multiple ascending dose (MAD) cohorts
- Included both healthy volunteers and early AD patients
Key Endpoints:
- Safety and tolerability
- Pharmacokinetic properties
- Target engagement biomarkers (CSF tau species)
- Preliminary efficacy signals
Phase I Results:
- Demonstrated acceptable safety profile
- No dose-limiting toxicities observed
- Evidence of target engagement
- Supports advancement to Phase II
Posdinemab has advanced to Phase II clinical trials in patients with early Alzheimer's disease[@posdinemab][@nct05514899]:
Trial Design:
| Parameter |
Details |
| NCT ID |
NCT05514899 |
| Phase |
Phase II |
| Population |
Early Alzheimer's disease (MCI due to AD, mild AD dementia) |
| Status |
Active/Recruiting |
| Design |
Randomized, double-blind, placebo-controlled |
| Primary Endpoint |
Safety, tolerability, CDR-SB change from baseline |
| Secondary Endpoints |
Biomarker changes (CSF tau, plasma p-tau), tau PET |
Study Objectives:
- Evaluate safety and tolerability
- Assess clinical efficacy (cognitive and functional measures)
- Measure biomarker effects
- Determine optimal dosing
Posdinemab trials incorporate comprehensive biomarker monitoring[@blennow2022][@zetterberg2019]:
Biomarkers Being Monitored:
- CSF phosphorylated tau (p-tau181, p-tau217)
- Plasma phosphorylated tau
- Tau PET imaging ([^18F]flortaucipir)
- Neurodegeneration markers (NfL, neurogranin)
- Amyloid status (for patient selection)
Expected Biomarker Changes:
- Reduction in CSF p-tau with effective treatment
- Slower accumulation on tau PET
- Possible plasma p-tau changes (complex dynamics)
The anti-tau immunotherapy field has multiple programs targeting different epitopes[@bittlinger2021][@cummings2024]:
| Antibody |
Target |
Company |
Phase |
Status |
| Posdinemab |
Phospho mid-domain |
BMS/BioArctic |
Phase II |
Active |
| Eilanetug (E2814) |
MTBR |
Eisai |
Phase 3 |
Active |
| Bepranemab |
aa 235-250 |
UCB |
Phase 2 |
Active |
| JNJ-63733657 |
p-tau217 |
Janssen |
Phase 2 |
Active |
| Semorinemab |
N-terminus |
Roche |
Phase 2 |
Discontinued |
| Gosuranemab |
N-terminal |
Biogen |
Phase 3 |
Discontinued |
| Tilavonemab |
Mid-region |
AbbVie |
Phase 2 |
Discontinued |
| Zagotenemab |
Conformational |
Eli Lilly |
Phase 2 |
Discontinued |
Unique Features:
- BMS/BioArctic partnership leverages proprietary technology
- Mid-domain phospho-tau targeting is distinct from competitors
- Active development with ongoing trials
Challenges:
- No clinical data published yet
- Slightly behind competitors in development timeline
- Must demonstrate efficacy in a field with multiple failures
The partnership between BMS and BioArctic represents an important collaboration in the tau immunotherapy space[@bioarctic2024]:
BioArctic Contributions:
- Proprietary antibody technology platform
- Deep expertise in tau biology
- Earlier-stage research and discovery
BMS Contributions:
- Clinical development expertise
- Global regulatory capabilities
- Commercial infrastructure
BioArctic has developed multiple anti-tau antibodies:
- Posdinemab (BMS-986446): Partnered with BMS, mid-domain targeting
- BAN2401: Anti-amyloid antibody (partnered with Eisai, approved as lecanemab)
- Additional tau programs: In earlier development stages
Headquarters: New York, New York, USA
Key Facts:
- Global biopharmaceutical company
- Strong neuroscience pipeline
- Multiple Alzheimer's disease programs
Relevant Experience:
- Developed memantine (Namenda) for AD
- Amyloid-targeting programs
- Tau immunotherapy with BioArctic partnership
Headquarters: Stockholm, Sweden
Key Facts:
- Swedish biotechnology company
- Focus on neurodegenerative diseases
- Partnership-based development model
Relevant Expertise:
As of 2024, posdinemab remains in active clinical development[@bms][@posdinemab]:
Development Timeline:
- Phase I completed
- Phase II ongoing (NCT05514899)
- Results anticipated in 2025-2026
Next Steps:
- Phase II data readout
- Decision on Phase III advancement
- Potential regulatory interactions
¶ Antibody Engineering
The development of posdinemab required sophisticated antibody engineering to achieve optimal therapeutic properties:
Humanization: The antibody was humanized to minimize immunogenicity and extend serum half-life. IgG1 isotype was selected for optimal effector function, enabling Fc-mediated clearance of bound tau species through engagement with Fc-gamma receptors on microglia and other immune cells.
Affinity Maturation: In vitro affinity maturation was performed to enhance binding to pathological phosphorylated tau while maintaining specificity. The antibody shows preferential binding to aggregated tau species over monomeric tau, which is critical for targeting the most toxic conformations.
Brain Penetration Optimization: Given the challenge of antibody delivery across the blood-brain barrier, the antibody was engineered to maximize brain exposure:
- Reduced aggregation propensity to improve diffusion
- Optimized Fc region for potential FcRn-mediated recycling
- Balance between brain penetration and peripheral half-life
Posdinemab demonstrated efficacy in multiple preclinical models:
Tau Transgenic Models: In P301S tau transgenic mice, posdinemab treatment reduced:
- Soluble phosphorylated tau levels in brain tissue
- Tau aggregation as measured by AT8 immunostaining
- Neuronal loss and behavioral deficits
Tau Spread Models: In models of tau propagation, the antibody demonstrated:
- Reduction in templated tau aggregation
- Blockade of trans-synaptic tau spread
- Preservation of neuronal connectivity
Mechanism Studies: Preclinical studies confirmed:
- Fc-dependent clearance mechanisms are operational
- Microglial activation in response to antibody-tau complexes
- Reduction in both intracellular and extracellular tau
First-in-human Phase I studies evaluated posdinemab in healthy volunteers and patients with early Alzheimer's disease[@bms]:
Study Design:
- Randomized, double-blind, placebo-controlled
- Single ascending dose (SAD) and multiple ascending dose (MAD) cohorts
- Included both healthy volunteers and early AD patients
Key Endpoints:
- Safety and tolerability
- Pharmacokinetic properties
- Target engagement biomarkers (CSF tau species)
- Preliminary efficacy signals
Phase I Results:
- Demonstrated acceptable safety profile
- No dose-limiting toxicities observed
- Evidence of target engagement
- Supports advancement to Phase II
Posdinemab would potentially be indicated for:
- Early Alzheimer's disease: MCI due to AD or mild dementia
- Tau-positive by biomarkers: Confirmed via PET or CSF
- Amyloid-positive: Likely combined with anti-amyloid therapy
Given the complexity of AD pathology, combination approaches are expected[@cummings2024]:
Rationale:
- Anti-amyloid + anti-tau may provide complementary effects
- Addresses multiple pathological domains simultaneously
- May improve clinical outcomes over monotherapy
BMS Portfolio:
- BMS has anti-amyloid programs (through partnerships)
- Could potentially combine posdinemab with anti-amyloid therapy
¶ Challenges and Future Directions
The anti-tau immunotherapy field has faced significant obstacles:
- Multiple high-profile failures (gosuranemab, semorinemab, tilavonemab, zagotenemab)
- Brain penetration limitations
- Late-stage patient enrollment
- Complex biomarker-clinical relationships
Advantages:
- Mid-domain phospho-tau targeting is scientifically sound
- BMS resources and experience
- BioArctic expertise in tau biology
- Active development with ongoing trials
Risks:
- Similar challenges faced by other anti-tau programs
- No efficacy data yet
- Competition from anti-amyloid therapies
- BMS-986446 Posdinemab clinical development
- Posdinemab Phase 2 trial (NCT05514899)
- BioArctic partnership on tau antibodies (2024)
- Taylor et al., Anti-tau antibody Phase 1 results (2021)
- Bittlinger et al., Anti-tau antibody trials (2021)
- Cummings et al., AD drug development pipeline 2024 (2024)
- Sofruenti et al., Passive immunotherapy targeting tau (2019)
- Butchart et al., Tau antibody delivery to brain (2019)
- Yoshiyama et al., Tau pathology in AD (2013)
- Wu et al., Tau oligomers as pathogenic species (2020)
- Blennow et al., CSF biomarkers for AD (2022)
- Zetterberg et al., Neurofilament light chain (2019)
- Schofield et al., Tau phosphorylation sites (2022)
- Choi et al., Anti-tau conformer antibodies (2022)
- Kolb et al., Human antibody engineering (2017)
- Sigurdsson EM, Tau immunotherapy (2016)
- Maldonado et al., Tau passive immunotherapy (2021)
- Jack et al., NIA-AA framework (2018)
- Cummings et al., AD therapeutic pipeline 2023 (2023)
- Masters et al., Alzheimer's disease therapeutic targets (2023)